Research programme: ubiquitin ligase inhibitors - Proteologics
Alternative Names: Midline-1 inhibitor - Proteologics; PRT14-2; PRT3; PRT42; PRT44; TRIM 18 inhibitor - ProteologicsLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Proteologics
- Developer GSK; Proteologics; University of Newcastle, Australia
- Class Antiasthmatics; Antineoplastics; Small molecules
- Mechanism of Action HIV replication inhibitors; Mid1 protein-inhibitors; Ubiquitin protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma; Cancer
- Discontinued HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in Australia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in Israel
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Israel